Gsk Share Discussion Threads

[mister md] 27/6/2024 08:52

And there I was topping up my holding at the 'cheap' price of 1600p a few days ago ... ffs !

[tradermichael] 27/6/2024 08:39

But here's some good news ....

GSK's Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis

· Omjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients

· Differentiated mechanism of action addresses key manifestations of myelofibrosis, namely anaemia, constitutional symptoms and splenomegaly

· In Japan, about 70% of patients diagnosed with primary myelofibrosis have moderate to severe anaemia at the time of diagnosis

[cumnor] 27/6/2024 08:38

Not just GSK vaccine-but GSK still the most effective.....
Moderna 50% after 2 years-GSK/Pfizer 75%+.
US not the only market and can see Moderna flop.

[wad collector] 27/6/2024 08:36

Buy time for me too; 1498 seems like a bargain. I somehow suspect this non-contract news will be forgotten soon.

The US old people need to save money to buy themselves more guns anyway....

[ny boy] 27/6/2024 08:34

Oh, I will buy a few more for the long term portfolio reasonable divi

[jojaken] 27/6/2024 08:31

GSK Plc slumped after US health officials recommended restricting vaccination with its RSV shot to people who are older and more at risk in a move that could reduce the market for the UK drugmaker's blockbuster vaccine. The guidance marks the second blow to GSK this week after it lost out to rival Pfizer Inc. on a contract to supply millions of doses of the vaccine to its home country. An advisory panel to the US Centers for Disease Control and Prevention only recommended vaccination in adults aged 60 to 74 if they were at risk of severe disease. RSV, or respiratory syncytial virus, is common but sometimes deadly, especially in the very young and the elderly.

[daneswooddynamo] 27/6/2024 08:28

US CDC recommending a reduced scope for RSV vaccine in its population has done the damage

[cumnor] 27/6/2024 08:21

Just bought in-divi now 4%-thanks. Markets crazy.....

[berny3] 27/6/2024 08:20

NHS selecting Pfizer over GSK for RSV vaccine. Seems crazy to me, drop is too much. But also crazy as GSK RSV is more effective than Pfizer. I imagine it is the knock on effect at what else will they choose Pfizer for.

[supermarky] 27/6/2024 08:18

So a few weeks back gsk was 1820 and now less than 1500Crazy.I am holding and riding this out.Waiting to see how this shapes up to top up at some point.How does one quantify to craziness? Sitting on my hands at the moment waiting for some sort of bottom to form.

[cumnor] 27/6/2024 08:18

Moderna RSV vaccine efficacy??

[tuftymatt] 27/6/2024 08:13

Yeah one hell of an ugly opening on no news that's for sure!!

Good luck all 👍🏻

[paulstills] 27/6/2024 08:11

Any idea what's happened here with the drop this morning?

[beergut] 27/6/2024 07:14

Up 18c in the after hours trading in the USNot that that will help with the open hereThe drop could be an over reaction to the British Government choosing Pfizer over Glaxo for some vaccines. Makes you wonder which Tory MP will get on the board of Pfizer after the election

[cumnor] 26/6/2024 21:55

? why the drop in the US??

[chc15] 26/6/2024 19:49

Lol this is nonsense, u need to look at holding announcements to know what's really going on. Check out 3i Group, it's last two holding announcements says it all. GSK is forever in the doldrums, although I have bought some at 1600 recently.

[pj84] 26/6/2024 11:40

The top 10 UK stocks the world’s best managers are buying

GSK no.4 in the list

[dplewis1] 25/6/2024 08:21

Yes, I agree. Thanks for bringing the point alive with the Prince Andrew analogy :)

[laurence llewelyn binliner] 25/6/2024 08:05

#dplewis, settling out of court is not always an admission of guilt, in some cases it is more cost effective and reputation damage limitation from the fallout of years of extended litigation..

In some cases it does nothing to dampen speculation though, ref our Prince that does not sweat.. (much).. :o)

[dplewis1] 25/6/2024 07:53

If there's no link to causing cancer why are they settling?

[tradermichael] 24/6/2024 08:09

GSK's Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis


· Omjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients
· Differentiated mechanism of action addresses key manifestations of myelofibrosis, namely anaemia, constitutional symptoms and splenomegaly
· In Japan, about 70% of patients diagnosed with primary myelofibrosis have moderate to severe anaemia at the time of diagnosis.

[tradermichael] 20/6/2024 09:32

GlaxoSmithKline Biologicals SA (GSK), a global leader in pharmaceuticals, and Imperial College London have announced a significant partnership.

This landmark agreement marks the beginning of an intensive exploration into the safety and efficacy of next generation thermostable RNA formulations and is a step forward in the realm of RNA-based vaccines through a 12-month validation study.

The nanoparticles, inspired by nature and developed by Professor Rongjun Chen and co-inventors at Imperial, have shown remarkable promise in protecting RNA-based vaccines and therapeutics and carrying them more effectively into cells. These formulations can enhance stability even at tropical temperatures and substantially reduce the dosage required for treatment.

"This partnership with GSK signifies a pivotal moment in our journey to unlock the full potential of RNA-based vaccines and therapeutics," commented Professor Rongjun Chen. "We are thrilled to embark on this validation study, confident that our innovative formulations will pave the way for safer, more effective and affordable treatments against a range of diseases."
Through this partnership, GSK aims to harness the transformative potential of Imperial’s technologies to advance the development of thermostable RNA-based vaccines. By combining GSK's expertise in pharmaceutical development with Imperial’s ground-breaking formulations, the collaboration holds promise for revolutionising the landscape of vaccine and therapeutic delivery.

The patented technologies have stemmed from the Future Vaccine Manufacturing Research Hub at Imperial, funded by the Department of Health and Social Care using UK Aid funding and managed by the Engineering and Physical Sciences Research Council (EPSRC).

[tradermichael] 18/6/2024 16:07

Sanofi has settled about 4,000 Zantac cases, and the Financial Times reported last month that Pfizer had settled more than 10,000 cases.